NCT01262963View on ClinicalTrials.gov

An Absorption, Distribution, Metabolism and Excretion (ADME) Study of Single Oral Dose [14C] GSK2118436 in Subjects With BRAF Mutant Solid Tumors

PHASE1CompletedINTERVENTIONAL

Enrollment

4

Participants

Timeline

Start Date

January 26, 2011

Primary Completion Date

April 8, 2011

Study Completion Date

April 8, 2011

Conditions

Cancer

Interventions

DRUG

GSK2118436

A single oral dose of 95 mg of GSK2118436 containing approximately 80 µCi of radioactivity

Trial Locations (1)

98418

GSK Investigational Site, Tacoma

Sponsors

Lead Sponsor

GlaxoSmithKline

All Listed Sponsors

lead

GlaxoSmithKline

INDUSTRY

NCT01262963 - An Absorption, Distribution, Metabolism and Excretion (ADME) Study of Single Oral Dose [14C] GSK2118436 in Subjects With BRAF Mutant Solid Tumors | Biotech Hunter | Biotech Hunter